Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2

Leukemia & Lymphoma
Haifan ZhangZhenping Zhu

Abstract

Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. Here we show that certain "liquid" tumors such as acute myeloid leukemia not only produce VEGF but also express functional VEGFR, resulting in an autocrine loop for tumor growth and propagation. In addition, the leukemia-derived VEGF can also stimulate the production of growth factors, including interleukin 6 (IL6) and granulocyte-macrophage colony stimulating factor (GM-CSF), by human endothelial cells, which in turn further promotes the growth of leukemia cells (the paracrine loop). A fully human anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-2C6, strongly blocks KDR/VEGF interaction and neutralizes VEGF-stimulated activation of KDR in endothelial cells. In a system where leukemia cells are co-cultured with endothelial cells, IMC-2C6 inhibits both the production of IL6 and GM-CSF by endothelial cells and the growth of leukemia cells. Finally, IMC-2C6 effectively blocks VEGF-induced migration of KDR+ human leukemia cells, and when administered in vivo, significantly prolonged survival of mice inoculated with KDR+ huma...Continue Reading

References

Jul 1, 1994·British Journal of Haematology·A VaccaF Dammacco
Apr 5, 1995·Journal of the National Cancer Institute·C A BoocockS K Smith
Oct 1, 1996·Cytokine & Growth Factor Reviews·M Klagsbrun, P A D'Amore
Sep 8, 1999·Science·B L ZieglerC Peschle
Sep 24, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·N Ferrara
Dec 10, 1999·International Journal of Cancer. Journal International Du Cancer·J ItakuraM Korc
Dec 22, 1999·British Journal of Cancer·G PruneriF Pezzella
Aug 23, 2000·The Journal of Clinical Investigation·S DiasS Rafii
Dec 20, 2000·The Journal of Investigative Dermatology·P M LacalS D'Atri
Apr 28, 2001·Cytokine & Growth Factor Reviews·J Hiscott
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·S DiasS Rafii
Dec 1, 2001·Expert Opinion on Biological Therapy·T G Zogakis, S K Libutti
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·Dan LuZhenping Zhu

❮ Previous
Next ❯

Citations

Jan 5, 2006·Annals of Hematology·Michael A Morgan, Christoph W M Reuter
Oct 31, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D H KimJ H Lipton
Jul 6, 2014·BioMed Research International·Floor C J van de WateringOtto C Boerman
Apr 25, 2007·Leukemia & Lymphoma·Rita FragosoSérgio Dias
Nov 23, 2005·Expert Opinion on Therapeutic Targets·Keren Paz, Zhenping Zhu
Apr 14, 2015·Seminars in Cancer Biology·W G JiangD Santini
Feb 21, 2007·Expert Opinion on Biological Therapy·Yiwen Li, Zhenping Zhu
Dec 26, 2006·Critical Reviews in Oncology/hematology·Xunwei DongRenchi Yang
Aug 30, 2012·European Journal of Haematology·Julian PaeslerKarl-Anton Kreuzer
Nov 7, 2013·Hematology·Houda Haouas
Jun 21, 2013·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Ryan D Nipp, Arati V Rao
Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael I KoukourakisUNKNOWN Tumour Angiogenesis Research Group
Aug 24, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bruno LarrivéeAly Karsan
Apr 4, 2021·Cytokine·Omid Karimdadi SarianiFarhad Zaker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.